
News from Endpoints News
Top Endpoints News News

Seoul · SeoulA South Korean biotech working on multi-specific autoimmune disease treatments is looking to make a leap into the US.
Curogen, based in Seoul and backed by local investors, announced Monday that it plans to open ...See the Story
Korean startup Curogen seeks global expansion, new funding to back autoimmune drugs

Eli Lilly · IndianapolisCHICAGO — Self-described “blunt pharma executives” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News at the annual ASCO conference. The biggest takeaway from a conversation with the Indianapolis ...See the Story
Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Breast Cancer(MedPage Today) -- CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09...See the Story
ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer
100% Center coverage: 2 sources